CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570)
C4 Therapeutics (NASDAQ: CCCC) advances a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of cells.
Company (IPO / Went public)
Phone: 617-231-0700
490 Arsenal Way
Suite 200
Watertown, 02472
Massachusetts, United States
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| C3-carbon linked glutarimide degronimers for target protein degradation | Nov 09, 2018 | Dec 01, 2020 | Patent |
| Spirocyclic degronimers for target protein degradation | Nov 09, 2018 | May 26, 2020 | Patent |
| Heterocyclic degronimers for target protein degradation | Nov 09, 2018 | May 12, 2020 | Patent |
| Cereblon binders for the degradation of ikaros | Sep 24, 2020 | Application | |
| Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety | Jun 16, 2020 | Application |
